Dynamic Contrast-Enhanced MR Imaging in a Phase Ⅱ Study on Neoadjuvant Chemotherapy Combining Rh-Endostatin with Docetaxel and Epirubicin for Locally Advanced Breast Cancer

Jia, Qianxin; Xu, Junqiang; Jiang, Weifeng; Zheng, Minwen; Wei, Mengqi; Chen, Jianghao; Yi, Huan

doi:10.7150/ijms.5123

Cited by 9 publications

(9 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Jia et al found that rh-endostatin inhibited angiogenesis of breast cancer, indirectly leading to tumor regression and dormancy [ 42 ]. The study also found that the combination of rh-endostatin in breast cancer can potentiate the anti-tumor effect of the neoadjuvant chemotherapy, and exacerbate tumor regression.…”

Section: Clinical Utility Of Rh-endostatin In Cancer Treatmentmentioning

confidence: 99%

Current Status and Study Progress of Recombinant Human Endostatin in Cancer Treatment

Shi

Qin

2018

Oncol Ther

View full text Add to dashboard Cite

Angiogenesis plays fundamentally critical roles in solid-tumor pathogenesis, growth, invasion and metastasis. Endostatin, one of the most potent anti-angiogenic factors, was first isolated in Folkman's lab in 1997, and was reported to dramatically shrink tumor blood formation. But its insoluble and unstable nature coupled with the high cost of synthesizing the endostatin protein doomed it for clinical cancer treatment. Intrigued by Folkman's pioneering discoveries, Chinese scientists found a way to refold the protein, making it cost-effective to manufacture a recombinant human endostatin, a soluble and stable form of endostatin. A number of clinical studies have demonstrated the significant survival benefit of rh-endostatin in treating late stage non-small-cell lung carcinoma (NSCLC) and, as a result, rh-endostatin (Endostar Ò ) was approved by the State Food and Drug Administration of China (CFDA) in September of 2005 as a treatment option for NSCLC. Since then, increasing bodies of clinical data and experience have been obtained from a variety of other different cancers, such as small cell lung cancer, NSCLC in other settings, including malignant serous effusion, melanoma, colon cancer, gastric cancer, breast cancer, nasopharyngeal cancers, and others. This review aims at summarizing current clinical data of rh-endostatin including its survival benefits, optimized dosages, routes of administration, recommended duration and frequency of treatment, predictive biomarkers, and its safety profile in lung cancers as well as other cancers.

show abstract

Section: Clinical Utility Of Rh-endostatin In Cancer Treatmentmentioning

confidence: 99%

Current Status and Study Progress of Recombinant Human Endostatin in Cancer Treatment

Shi

Qin

2018

Oncol Ther

View full text Add to dashboard Cite

show abstract

“…for the treatment of non-small-cell lung cancer in combination with vinorelbine-cisplatin (phase III trial [208]). Several phase I [209,210], and II [211][212][213][214][215][216][217][218][219] clinical trials have been conducted these last five years in patients with melanoma [213], nasopharyngeal carcinoma [215], head and neck carcinoma [218] lung [211,216,217,219,220], pancreatic [209],…”

Section: Ecm Bioactive Fragments As Drugs and Biomarkersmentioning

confidence: 99%

Fragments generated upon extracellular matrix remodeling: Biological regulators and potential drugs

2019

View full text Add to dashboard Cite

“…As a result, non-invasive imaging modalities are being evaluated to predict patients likely to respond early in their therapy as a method of delivering personalized therapeutic cancer therapy (6–8). Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) has been evaluated to assess early tumor response following chemotherapy (9–11) or XRT (12–14). DCE-MRI can retrieve pharmacokinetic parameters of an MR contrast agent in a target tissue monitoring the dynamic change of contrast concentration over time (15).…”

Section: Introductionmentioning

confidence: 99%

“…DCE-MRI can retrieve pharmacokinetic parameters of an MR contrast agent in a target tissue monitoring the dynamic change of contrast concentration over time (15). Effective killing of cancer cells alters microvasculature in a tumor, represented by the change of K trans (forward volume transfer constant: wash-in rate) values that are quantifiable from DCE-MR images (11,14). The early assessment of tumor response may improve clinical outcomes by discontinuing a failing treatment in a timely manner.…”

Section: Introductionmentioning

confidence: 99%

Dynamic contrast‐enhanced MRI evaluates the early response of human head and neck tumor xenografts following anti‐EMMPRIN therapy with cisplatin or irradiation

Kim

Hartman

Zhai

et al. 2015

Magnetic Resonance Imaging

View full text Add to dashboard Cite

Purpose To assess the early therapeutic effects of anti-EMMPRIN antibody with/without cisplatin or X-ray radiation in head and neck cancer mouse models using dynamic contrast enhanced magnetic resonance imaging (DCE-MRI). Materials and Methods Mice bearing SCC1 (or OSC19) tumor xenografts were treated with anti-EMMPRIN antibody, radiation, cisplatin, or anti-EMMPRIN antibody plus cisplatin (or radiation) for a week (n=4–5 per group). DCE-MRI was carried out on a 9.4T small animal MR scanner on days 0, 3, and 7, and Ktrans values were averaged in 0.5-mm thick peripheral tumor region. Ki67 and CD31 staining were implemented for all tumors after imaging. Results The Ktrans changes of SCC1 and OSC19 tumors treated with anti-EMMPRIN antibody for 3 days were −18±8% and 4±7%, respectively, which were significantly lower than those of control groups (39±5% and 45±7%; p=0.0025 and 0.0220, respectively). When cisplatin was added, those were −42±9% and −44±9%, respectively, and with radiation, −45±9% and −27±10%, respectively, which were also significantly lower than those of control groups (p<0.0001 for all four comparisons). In the eight groups untreated (served as control) or treated with anti-EMMPRIN antibody with/without cisplatin or radiation, the mean Ktrans change for 3 days was significantly correlated with the mean tumor volume change for 7 days (r=0.74, p=0.0346), Ki67 expressing cell density (r=0.96, p=0.0001) and CD31 density (r=0.84, p=0.0084). Conclusion DCE-MRI might be utilized to assess the early therapeutic effects of anti-EMMPRIN antibody with/without chemotherapy or radiotherapy in head and neck cancer.

show abstract

Dynamic Contrast-Enhanced MR Imaging in a Phase Ⅱ Study on Neoadjuvant Chemotherapy Combining Rh-Endostatin with Docetaxel and Epirubicin for Locally Advanced Breast Cancer

Cited by 9 publications

References 33 publications

Current Status and Study Progress of Recombinant Human Endostatin in Cancer Treatment

Current Status and Study Progress of Recombinant Human Endostatin in Cancer Treatment

Fragments generated upon extracellular matrix remodeling: Biological regulators and potential drugs

Dynamic contrast‐enhanced MRI evaluates the early response of human head and neck tumor xenografts following anti‐EMMPRIN therapy with cisplatin or irradiation

Contact Info

Product

Resources

About